Le fardeau de plus en plus lourd des maladies inflammatoires de l'intestin du Canada

Conclusions du rapport 2023 sur l'impact des maladies inflammatoires de l'intestin au Canada publié par Chrohn et Colite Canada

Auteurs-es

  • Ellen Kuenzig
  • Gilaad Kaplan
  • Eric Benchimol

Résumé

The Impact of Inflammatory Bowel Disease report, produced by the Canadian Gastro-Intestinal Epidemiology Consortium (cangiec.ca) for Crohn’s and Colitis Canada is a serial policy report produced every 3–5 years that summarizes the existing literature on the epidemiology, burden, and impact of inflammatory bowel disease (IBD) in Canada and identifies knowledge gaps. Its goal is to inform people living with IBD and their caregivers, donors, physicians, researchers, policy makers, and other stakeholders about the current burden of IBD in Canada. It plays an integral role for Crohn’s and Colitis Canada’s advocacy efforts. In addition, the report informs the research funding policy of the health charity, which is the second largest non-governmental funder of IBD research in the world. The latest iteration of this report was released on June 1, 2023 and is available here. This article summarizes the current epidemiology of IBD in Canada and discusses its implications for clinical care in 2024 and beyond.

Biographies de l'auteur-e

Ellen Kuenzig

Ellen Kuenzig is a Senior Research Associate at the SickKids IBD Centre at The Hospital for Sick Children and the Child Health Evaluative Sciences program at the SickKids Research Institute. Dr. Kuenzig is an epidemiologist and health services researcher. She is a member of Crohn’s and Colitis Canada’s Scientific and Medical Advisory Council and the Scientific Committee of the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC), which conducts epidemiology, pharmacoepidemiology, outcomes, and health services research using the health administrative data from multiple provinces.

Gilaad Kaplan

Dr. Kaplan is a Professor in the Cumming School of Medicine at the University of Calgary. Dr. Kaplan is a gastroenterologist who is internationally renowned for studying the global epidemiology of inflammatory bowel disease (IBD). He is an Associate Editor of Gastroenterology. In 2019, Dr. Kaplan was elected to the International Organization of the study of IBD (IOIBD). Clarivate, Web of Science named Dr. Kaplan a Highly Cited Researcher (2020-2023) in recognition of being in the top one percent of cited researchers. In 2021, Dr. Kaplan received Crohn’s and Colitis Canada’s Research Leader Award and was inducted into the Canadian Academy of Health Sciences. He is a Killam Laureate, receiving the Killam Annual Professor Award in 2022. His research has been widely cited in the news media including Time Magazine, BBC, The New York Times, and Scientific American.

Eric Benchimol

Eric Benchimol is the Northbridge Financial Corporation Chair in Inflammatory Bowel Disease (IBD) and a pediatric gastroenterologist at the SickKids IBD Centre at The Hospital for Sick Children in Toronto. He is also a Professor in the Department of Paediatrics and the Institute for Health Policy, Management and Evaluation in the Temerty Faculty of Medicine of University of Toronto. Dr. Benchimol is also a Senior Core Scientist at ICES and Senior Scientist at the SickKids Research Institute. He is an epidemiologist, and chairs the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC), which conducts epidemiology, pharmacoepidemiology, outcomes, and health services research using the health administrative data from multiple provinces.

Références

Rose KL, Sherman PM, Cooke-Lauder J, Mawani M, Benchimol EI, Kaplan GG, et al. The Impact of Inflammatory Bowel Disease in Canada 2018: IBD Research Landscape in Canada. Journal of the Canadian Association of Gastroenterology. 2018;390(10114):2769 - 11.

Windsor JW, Kuenzig ME, Murthy SK, Bitton A, Bernstein CN, Jones JL, et al. The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary. Journal of the Canadian Association of Gastroenterology. 2023;6(Supplement_2):S1-S8.

Benchimol EI, Kaplan GG, Bernstein CN, Bitton A, Jones JL, Kuenzig ME, et al. 2023 Impact of Inflammatory Bowel Disease in Canada2023. Available from: https://crohnsandcolitis.ca/Crohns_and_Colitis/documents/reports/2023-IBD-Report-English-LR.pdf?ext=.pdf.

Coward S, Benchimol EI, Bernstein CN, Avina-Zubieta A, Bitton A, Carroll MW, et al. Forecasting the incidence and prevalence of inflammatory bowel disease: a Canadian nationwide analysis. Am J Gastroenterol. 2024.

Coward S, Benchimol EI, Kuenzig ME, Windsor JW, Bernstein CN, Bitton A, et al. The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBD. Journal of the Canadian Association of Gastroenterology. 2023;6(Supplement_2):S9-S15.

Benchimol EI, Bernstein CN, Bitton A, Carroll MW, Singh H, Otley AR, et al. Trends in epidemiology of pediatric inflammatory bowel disease in Canada: distributed network analysis of multiple population-based provincial health administrative databases. The American Journal of Gastroenterology. 2017;112:1120 - 34.

Pena-Sanchez JN, Osei JA, Marques Santos JD, Jennings D, Andkhoie M, Brass C, et al. Increasing Prevalence and Stable

Incidence Rates of Inflammatory Bowel Disease Among First Nations: Population-Based Evidence From a Western Canadian Province. Inflamm Bowel Dis. 2022;28(4):514-22.

Benchimol EI, Mack DR, Guttmann A, Nguyen GC, To T, Mojaverian N, et al. Inflammatory Bowel Disease in Immigrants to Canada And Their Children: A PopulationBased Cohort Study. The American Journal of Gastroenterology. 2015;110(4):553 - 63.

Dhaliwal J, Tuna M, Shah BR, Murthy S, Herrett E, Griffiths AM, et al. Incidence of Inflammatory Bowel Disease in South Asian and Chinese People: A Population-Based Cohort Study from Ontario, Canada. Clin Epidemiol. 2021;13:1109-18.

Hracs L, Windsor J, Gorospe J, Cummings M, Coward S, Buie M, et al. [Pre-print] The global evolution of inflammatory bowel disease across four epidemiologic stages2024 January 30,

Available from: https://www.researchsquare.com/article/rs-3846147/v1.

Ng SC, Shi HY, Hamidi N, Underwood FE, Mphil WT, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of populationbased studies. The Lancet. 2018;390(10114):2769 - 78.

Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology. 2021;18(1):56-66.

Herauf M, Coward S, Pena-Sanchez JN, Bernstein CN, Benchimol EI, Kaplan GG, et al. Commentary on the Epidemiology of Inflammatory Bowel Disease in Compounding Prevalence Nations: Toward Sustaining Healthcare Delivery. Gastroenterology. 2024.

Raygoza Garay JA, Turpin W, Lee SH, Smith MI, Goethel A, Griffiths AM, et al. Gut Microbiome Composition Is Associated With Future Onset of Crohn’s Disease in Healthy First-Degree Relatives. Gastroenterology. 2023;165(3):670-81.

Shaffer SR, Kuenzig ME, Windsor JW, Bitton A, Jones JL, Lee K, et al. The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations—IBD in Seniors. Journal of the Canadian Association of Gastroenterology. 2023;6(Supplement_2):S45-S54.

Kuenzig ME, Manuel DG, Donelle J, Benchimol EI. Life expectancy and health-adjusted life expectancy in people with inflammatory bowel disease. Cmaj. 2020;192(45):E1394-E402.

Nguyen GC, Bouchard S, Diong C, and PA, Care through Centres of Excellence (PACE) Network. Access to Specialists and Emergency Department Visits in Inflammatory Bowel Disease: A Population-Based Study. J Crohn’s Colitis. 2018;13(3):330-6.

Kuenzig ME, Stukel TA, Kaplan GG, Murthy SK, Nguyen GC, Talarico R, et al. Variation in care of patients with elderlyonset inflammatory bowel disease in Ontario, Canada: A population-based cohort study. Journal of the Canadian Association of Gastroenterology. 2020;4(2):e16-e30.

Leddin D, Carroll M, Gillis C, Cehovin A. Gastroenterology Practitioner and Trainee Numbers in Canada 2018: Annual Report From the Canadian Association of Gastroenterology. J Can Assoc Gastroenterol. 2021;4(2):52-6.

Statistics Canada. Table 17-10-0009-01 Population estimates, quarterly. 2023.

Kuenzig ME, Benchimol EI, Lee L, Targownik LE, Singh H, Kaplan GG, et al. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. Journal of the Canadian Association of Gastroenterology. 2018;110(9):1324 - 17.

Kuenzig ME, Coward S, Targownik LE, Murthy SK, Benchimol EI, Windsor JW, et al. The 2023 Impact of Inflammatory Bowel Disease in Canada: Direct Health System and Medication Costs. Journal of the Canadian Association of Gastroenterology. 2023;6(Supplement_2):S23-S34.

Kuenzig ME, Im JHB, Coward S, Windsor JW, Kaplan GG, Murthy SK, et al. The 2023 Impact of Inflammatory Bowel Disease in Canada: Indirect (Individual and Societal) and Direct Out-of-Pocket Costs. Journal of the Canadian Association of Gastroenterology. 2023;6(Supplement_2):S16-S22.

Téléchargements

Publié

2024-06-05

Comment citer

1.
Le fardeau de plus en plus lourd des maladies inflammatoires de l’intestin du Canada: Conclusions du rapport 2023 sur l’impact des maladies inflammatoires de l’intestin au Canada publié par Chrohn et Colite Canada. Can IBD Today [Internet]. 5 juin 2024 [cité 31 mars 2026];2(1):5–11. Disponible à: https://canadianibdtoday.com/article/view/2-1-Kuenzig_et_al

Numéro

Volume 2, Issue 1, Spring 2024

Rubrique

Articles

Licence

© Canadian IBD Today 2024

Licence Creative Commons

Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.

Comment citer

1.
Le fardeau de plus en plus lourd des maladies inflammatoires de l’intestin du Canada: Conclusions du rapport 2023 sur l’impact des maladies inflammatoires de l’intestin au Canada publié par Chrohn et Colite Canada. Can IBD Today [Internet]. 5 juin 2024 [cité 31 mars 2026];2(1):5–11. Disponible à: https://canadianibdtoday.com/article/view/2-1-Kuenzig_et_al